• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

    5/9/22 4:01:00 PM ET
    $ALXO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALXO alert in real time by email

    SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology") (NASDAQ:ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the first quarter ended March 31, 2022 and provided clinical development and operational highlights.

    "Throughout the first quarter, we continued to realize significant progress advancing our lead program, evorpacept, through multiple clinical trials," said Jaume Pons, Ph.D., Founder, President and Chief Executive Officer of ALX Oncology. "Our highlights include dosing the first patient in ASPEN-06, our Phase 2/3 study testing evorpacept in combination with ramucirumab, trastuzumab, and paclitaxel for the treatment of patients with HER2-positive gastric cancer or gastroesophageal junction ("GEJ") cancer and the U.S. Food and Drug Administration ("FDA") granting Orphan Drug Designation ("ODD") to evorpacept for the treatment of patients with gastric/GEJ cancer."

    "Looking ahead, we are excited for clinical milestones by year-end including the expected dose optimization readout of a Phase 1b clinical trial of evorpacept in combination with azacitidine in patients with myelodysplastic syndromes ("MDS") (ASPEN-02) and updates on our Phase 1/2 collaboration with Zymeworks in evaluating the combination of evorpacept and zanidatamab in patients with HER2-positive breast cancer and other solid tumors," Dr. Pons continued.

         

    Recent Clinical Developments for Evorpacept

    • Initiation of a Phase 2/3 Study of Evorpacept for the Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Cancer (ASPEN-06)
      • In March 2022, the first patient was dosed in the Phase 2/3 ASPEN-06 study evaluating the combination of evorpacept, a next generation CD47 blocker, and CYRAMZA® (ramucirumab), Eli Lilly and Company's anti-VEGFR2 antibody, added to trastuzumab and paclitaxel for the treatment of patients with HER2-positive gastric/GEJ cancer.
      • ASPEN-06 (NCT05002127) is a randomized Phase 2 (open-label) / Phase 3 (double-blind), international, multi-center study to evaluate the efficacy of evorpacept in combination with ramucirumab, trastuzumab, and paclitaxel for the treatment of patients whose tumors have progressed following treatment with HER2-targeted therapy and chemotherapy. Approximately 450 adult patients will be enrolled in the study across both phases.
    • FDA Granted ODD for Evorpacept for the Treatment of Patients with Gastric/GEJ Cancer
      • In January 2022, ALX Oncology announced that the FDA granted ODD to evorpacept, a next-generation CD47 blocker, for the treatment of patients with gastric/GEJ cancer.

    Recent Corporate Updates

    • Appointed Itziar Canamasas, Ph.D., to its Board of Directors
      • In April 2022, ALX Oncology announced the appointment of Itziar Canamasas, Ph.D., to its Board of Directors (the "Board"). With more than 20 years of biopharmaceutical industry experience, Dr. Canamasas brings expertise in driving business growth and operational excellence.

    First Quarter 2022 Financial Results:

    • Cash, Cash Equivalents and Investments: Cash, cash equivalents and investments as of March 31, 2022 were $341.7 million. ALX Oncology believes its cash, cash equivalents and investments are sufficient to fund planned operations through mid-2024.
    • Research and Development ("R&D") Expenses: R&D expenses consist primarily of pre-clinical, clinical and manufacturing expenses related to the development of ALX Oncology's current lead product candidate, evorpacept, and R&D employee-related expenses. These expenses for the three months ended March 31, 2022, were $17.1 million, compared to $9.8 million for the prior-year period. The increase in expenses during the three months ended March 31, 2022 compared to the three months ended March 31, 2021 were primarily attributable to an increase of $2.6 million in clinical and development costs primarily due to manufacturing of clinical trial materials to support a higher number of active clinical trials and future expected patient enrollment related to the advancement of evorpacept, as well as an increase of $0.9 million related to the collaboration with Tallac Therapeutics, Inc., an increase of $2.1 million in personnel related costs driven by headcount growth, an increase of $1.5 million in stock-based compensation expense due to additional awards granted since March 31, 2021 and an increase of $0.6 million in other research costs due primarily to an increase in facility costs related to the expansion of our new laboratory space.
    • General and Administrative ("G&A") Expenses: G&A expenses consist primarily of administrative employee-related expenses, legal and other professional fees, patent filing and maintenance fees, and insurance. These expenses for the three months ended March 31, 2022, were $7.7 million, compared to $4.4 million for the prior-year period. The expense increases during the three months ended March 31, 2022 compared to the three months ended March 31, 2021 were primarily attributable to an increase of $2.2 million in stock-based compensation expense due to additional awards granted since March 31, 2021 and an increase of $0.8 million in other costs primarily driven by an increase in corporate legal fees, regulatory related filing fees and facility and information technology costs.
    • Net loss: GAAP net loss was $24.5 million for the first quarter ended March 31, 2022, or $0.60 per basic and diluted share, as compared to a net loss of $14.2 million for the first quarter ended March 31, 2021, or $0.35 per basic and diluted share. Non-GAAP net loss was $19.0 million for the first quarter ended March 31, 2022, as compared to a net loss of $12.4 million for the first quarter ended March 31, 2021. A reconciliation of GAAP to non-GAAP financial results can be found at the end of this news release.

    About ALX Oncology

    ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology's lead product candidate, evorpacept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpacept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of evorpacept for the treatment of multiple solid tumor indications and hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndromes.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements regarding future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, plans and objects of management for future operations, as well as statements regarding industry trends. Such forward-looking statements are based on ALX Oncology's beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology's actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in ALX Oncology's filings with the Securities and Exchange Commission ("SEC"), including ALX Oncology's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents ALX Oncology files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.



    ALX ONCOLOGY HOLDINGS INC.

    Condensed Consolidated Statements of Operations

    (unaudited)

    (in thousands, except share and per share amounts)

      Three Months Ended 
      March 31, 
      2022  2021 
    Operating expenses:      
    Research and development $17,073  $9,849 
    General and administrative  7,674   4,359 
    Total operating expenses  24,747   14,208 
    Loss from operations  (24,747)  (14,208)
    Interest income  225   25 
    Other income (expense), net  (11)  (2)
    Net loss $(24,533) $(14,185)
    Net loss per share, basic and diluted $(0.60) $(0.35)
    Weighted-average shares of common stock used to

    compute net loss per shares, basic and diluted
      40,616,302   40,055,435 
     
     

    Condensed Consolidated Balance Sheet Data

    (unaudited)

    (in thousands)

      March 31,

    2022
      December 31,

    2021
     
    Cash, cash equivalents and investments $341,705  $363,667 
    Total assets $363,676  $380,183 
    Total liabilities $20,080  $17,134 
    Accumulated deficit $(226,518) $(201,985)
    Total stockholders' equity $343,596  $363,049 
             
             

    GAAP to Non-GAAP Reconciliation

    (unaudited)

    (in thousands)

      Three Months Ended 
      March 31, 
      2022  2021 
    GAAP net loss, as reported $(24,533) $(14,185)
    Adjustments:        
    Stock-based compensation expense  5,501   1,800 
    Non-GAAP net loss $(19,032) $(12,385)
             

    Use of Non-GAAP Financial Measures

    We supplement our consolidated financial statements presented on a GAAP basis by providing additional measures which may be considered "non-GAAP" financial measures under applicable SEC rules. We believe that the disclosure of these non-GAAP financial measures provides our investors with additional information that reflects the amounts and financial basis upon which our management assesses and operates our business. These non-GAAP financial measures are not in accordance with generally accepted accounting principles and should not be viewed in isolation or as a substitute for reported, or GAAP, net loss, and are not a substitute for, or superior to, measures of financial performance performed in conformity with GAAP.

    "Non-GAAP net loss attributable to common stockholders" is not based on any standardized methodology prescribed by GAAP and represent GAAP net loss adjusted to exclude stock-based compensation expense. Non-GAAP financial measures used by ALX Oncology may be calculated differently from, and therefore may not be comparable to, non-GAAP measures used by other companies.

     



    Investor Contact:
    
    Peter Garcia
    Chief Financial Officer, ALX Oncology
    (650) 466-7125 Ext. 113
    [email protected]
    
    Argot Partners
    (212)-600-1902
    [email protected]
    
    Media Contact:
    
    Karen Sharma
    MacDougall
    (781) 235-3060
    [email protected]

    Primary Logo

    Get the next $ALXO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALXO

    DatePrice TargetRatingAnalyst
    3/6/2025$2.00 → $3.00Hold → Buy
    Jefferies
    12/19/2024$12.00 → $2.00Buy → Hold
    Jefferies
    3/8/2024$10.00 → $14.00Buy → Hold
    Stifel
    12/8/2023$8.00 → $18.00Hold → Buy
    Jefferies
    3/1/2022$60.00 → $36.00Buy
    Stifel
    12/22/2021$65.00 → $25.00Buy → Hold
    Jefferies
    9/30/2021$106.00Buy
    Stifel
    More analyst ratings

    $ALXO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by SVP, FINANCE AND CAO Pinto Shelly

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      4/15/25 4:29:19 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Sandler Alan B.

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      4/15/25 4:19:34 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Shantharam Harish

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      4/15/25 4:16:28 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALXO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hemrajani Rekha bought $46,404 worth of shares (30,000 units at $1.55), increasing direct ownership by 1,000% to 33,000 units (SEC Form 4)

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      12/4/24 4:17:28 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: CHIEF FINANCIAL OFFICER Garcia Peter S bought $102,338 worth of shares (12,000 units at $8.53), increasing direct ownership by 11% to 122,348 units (SEC Form 4)

      4/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      6/24/24 9:00:55 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF FINANCIAL OFFICER Garcia Peter S bought $102,338 worth of shares (12,000 units at $8.53), increasing direct ownership by 11% to 122,348 units (SEC Form 4)

      4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)

      6/17/24 7:29:53 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALXO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ALX Oncology upgraded by Jefferies with a new price target

      Jefferies upgraded ALX Oncology from Hold to Buy and set a new price target of $3.00 from $2.00 previously

      3/6/25 7:17:16 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology downgraded by Jefferies with a new price target

      Jefferies downgraded ALX Oncology from Buy to Hold and set a new price target of $2.00 from $12.00 previously

      12/19/24 7:28:17 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology downgraded by Stifel with a new price target

      Stifel downgraded ALX Oncology from Buy to Hold and set a new price target of $14.00 from $10.00 previously

      3/8/24 7:21:35 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALXO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

      SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

      11/14/24 7:22:54 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

      SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

      11/14/24 6:58:27 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ALX Oncology Holdings Inc.

      SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

      11/14/24 3:02:41 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALXO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference

      SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that management will participate in the Jefferies 2025 Global Healthcare Conference. Details are as follows: Format: Fireside Chat Date: Thursday, June 5, 2025Time: 1:25 PM ETLocation: New York, NYWebcast link: Available here The live webcast of the Jefferies fireside chat can be accessed by visiting the Investors section of ALX Oncology's website at www.alxoncology.com under the Events section of the Even

      5/30/25 8:00:21 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event

      - A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the therapeutic window by reducing toxicity - Following recent IND clearance from U.S. FDA, ALX2004 will enter clinical studies mid-year 2025 with initial safety data anticipated in 1H 2026 - Trials evaluating the Company's lead investigational therapy, CD47-blocker evorpacept, in breast and colorectal cancers planned to initiate in mid-2025 with multiple key inflection points from evorpacept and ALX2004 development programs anticipated in 2026 SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSW

      5/20/25 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025

      SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that it will host a webcast event on May 20, 2025, to provide an update on ALX2004, the Company's potentially best- and first-in-class investigational antibody-drug conjugate (ADC). The webcast will highlight the novel mechanism of action, preclinical data and clinical development strategy for ALX2004 following clearance of the Investigational New Drug application from the U.S. Food and Drug Administration e

      5/13/25 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALXO
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by ALX Oncology Holdings Inc.

      SCHEDULE 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

      5/15/25 4:15:24 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by ALX Oncology Holdings Inc.

      SCHEDULE 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)

      5/15/25 4:05:22 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by ALX Oncology Holdings Inc.

      10-Q - ALX ONCOLOGY HOLDINGS INC (0001810182) (Filer)

      5/8/25 4:01:21 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALXO
    Financials

    Live finance-specific insights

    See more
    • ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025

      SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced plans to report its first quarter 2025 financial results on Thursday, May 8th, 2025, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About ALX OncologyALX Oncology (NASDAQ:ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives. ALX Oncology's lea

      5/2/25 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

      SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced plans to report its fourth quarter and full year 2024 financial results on Thursday, March 6th, 2025, before market open.  The company will not be hosting a teleconference in conjunction with its financial results press release. About ALX OncologyALX Oncology (NASDAQ:ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives.

      2/27/25 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer

      Oral presentation at 2025 ASCO Gastrointestinal Cancers Symposium today highlights evorpacept as the first CD47 blocker to show substantial tumor response and a well-tolerated safety profile in a prospective randomized trialGreatest benefit observed among patients with confirmed HER2-positive cancer, as demonstrated by either fresh biopsy or ctDNA HER2-expression, with confirmed ORR of 48.9% and mDOR of 15.7 months vs. 24.5% ORR and mDOR of 9.1 months in the control group, and a PFS Hazard Ratio of 0.64Company to host conference call and investor webcast today at 1:00 PM PT/4:00 PM ET SOUTH SAN FRANCISCO, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology

      1/23/25 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALXO
    Leadership Updates

    Live Leadership Updates

    See more
    • ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors

      Mr. Shantharam is a proven biotech industry executive with over two decades of senior leadership experience in finance, commercial and corporate operationsDr. Klencke is a seasoned clinical leader in oncology drug development with more than 20 years of industry experienceDr. Takimoto brings a distinguished track record in oncology and drug development with 17 years of industry experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients' lives, today announced the appointmen

      1/22/25 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients' lives, announced today the appointment of Alan Sandler, M.D., as Chief Medical Officer. "Dr. Sandler's breadth of experience and demonstrated leadership capabilities across oncology and drug development, as well as his in-depth knowledge of ALX Oncology while he was a member of our Board, will be instrumental in helping us achieve our near- and longer-term objectives," said Jason Lettmann, Chief Executive Officer at

      11/14/24 8:00:00 AM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update

      SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. "Our team continues to make significant progress in the advancement of our evorpacept development pipeline across multiple oncology indications," said Jason Lettmann, Chief Executive Officer of ALX Oncology. "Data readouts across our Phase 1 and 2 clinical trials highlight the potential of evorpacept as a disruptive therapy in combination with anti

      8/8/24 4:05:00 PM ET
      $ALXO
      Biotechnology: Pharmaceutical Preparations
      Health Care